Search this site
967 results found with an empty search
Blog Posts (882)
- Living With the “What If”: Fear of Recurrence and Fear of Progression
Why the fear shows up, what sets it off, and what the research says actually helps. A headache that lingers a day too long. A scan date circled on the calendar. A friend’s news that hits a little too close to home. For many people touched by breast cancer, moments like these bring a familiar question rushing back: What if it’s back? What if it’s growing? What if the drugs are not working? By Laura Carfang, Ed.D. EDUCATION | MENTAL HEALTH Key Takeaways More than half of cancer survivors experience at least moderate fear of recurrence, and about 1 in 5 experience high levels. Fear of progression in metastatic breast cancer is a distinct experience that calls for different support. Common triggers include scans, new symptoms, anniversaries, and other people’s cancer stories. Cognitive behavioral therapy, mindfulness, and structured programs like ConquerFear have been shown in randomized trials to reduce fear of recurrence. ASCO recommends regular screening for anxiety and depression, and you can ask your care team for support at any time. Two Fears, Two Different Realities Fear of recurrence is the worry that cancer will return after treatment for early-stage breast cancer. It’s one of the most common concerns survivors report. A large international analysis of more than 9,000 people found that about 59% of cancer survivors and patients experience at least moderate fear of recurrence, and about 1 in 5 experience high levels. Women and younger people tend to report more. Fear of progression is the worry that metastatic breast cancer (MBC) will grow, spread, or stop responding to treatment. Researchers increasingly see it as its own experience, not just a version of fear of recurrence. People living with MBC aren’t waiting to find out if cancer will change. They’re living with a disease that needs ongoing treatment, and the uncertainty looks different. Both fears are normal responses to a very real experience. They become a problem when they start crowding out sleep, relationships, plans, or joy. The good news is that there are proven ways to turn the volume down. Understanding Your Fear Triggers Fear rarely arrives out of nowhere. It usually has a trigger, something that reminds the brain of danger. Knowing yours won’t make the fear disappear, but it can make it feel less like an ambush. Common triggers include: • Medical moments: upcoming scans, waiting for results (often called “scanxiety”), routine checkups, or a change in your treatment plan. • Body signals: a new ache, cough, lump, or fatigue that your mind quickly connects to cancer. • Dates and anniversaries: the day you were diagnosed, finished treatment, or got difficult news. • Other people’s stories: a friend’s recurrence, a celebrity’s diagnosis, or a post in an online group. • Media and reminders: news coverage, October’s sea of pink, or walking past the hospital. • Transitions: finishing active treatment, when appointments space out and the “safety net” feels thinner. For people living with MBC, triggers often include scan cycles, rising tumor markers, a new symptom, or talk of changing treatment. Research also shows that people with more severe physical symptoms tend to report stronger fear of progression, which is one more reason good symptom management matters. Something to try: For two weeks, jot down when the fear spikes and what was happening right before. Patterns often appear quickly. Those patterns are useful to share with your care team or a counselor. Coping Strategies Backed By Research The goal isn’t to never feel afraid. It’s to keep fear from running your life. These approaches have been tested in clinical studies. Cognitive behavioral therapy (CBT) CBT helps you notice anxious thought patterns, like jumping from “my back hurts” to “the cancer has spread,” and respond to them in a more balanced way. A review of 17 randomized trials found that CBT-based programs appear to reduce fear of recurrence in people who have been diagnosed with breast cancer and who have finished active treatment. ConquerFear and similar programs ConquerFear is a structured program built specifically for fear of recurrence. It teaches skills like shifting attention away from worry, loosening the grip of “worrying keeps me safe” beliefs, mindfulness, sensible approaches to self-checking, and setting goals based on what matters to you. In a randomized trial, 222 people with a history of breast cancer, colorectal cancer, and melanoma, who completed five sessions had greater drops in fear than those who received relaxation training, with benefits lasting at least six months. An online group version for breast cancer survivors has also shown lasting benefits. Mindfulness Mindfulness means paying attention to the present moment without judging it. Instead of arguing with a scary thought, you notice it and let it pass. In another randomized trial focusing on those diagnosed with breast cancer found that six-week mindfulness-based stress reduction program reduced fear of recurrence, stress, and anxiety. National guidelines from ASCO and the Society for Integrative Oncology also recommend mindfulness-based approaches for anxiety and depression in people with cancer. Support designed for metastatic disease Most fear-of-recurrence programs were built for people with an early-stage cancer diagnosis, and researchers have found that people living with MBC need something different: strategies for living well with uncertainty, not just reassurance. Two examples: • CALM (Managing Cancer and Living Meaningfully): a short therapy, usually three to six sessions, for people with advanced cancer. In a trial of 305 people, CALM reduced depression symptoms and helped people prepare for the future compared with usual care. • Online self-guided programs: early studies of a web-based program for women with MBC showed small improvements in fear of progression. Larger trials are underway. Everyday tools that support the bigger picture • Make a scan plan. Ask how and when you’ll get results, and plan something steadying for the waiting days. • Agree on a symptom rule. Ask your team which symptoms need a call, and how long to watch others. This turns endless worrying into a clear next step. • Move your body. Structured physical activity is among the approaches ASCO recommends for anxiety and depression after cancer. • Limit the doom-scroll. It’s okay to step back from groups or news that leave you more frightened. • Name it out loud. Telling someone, “I'm scared about my scan” often takes some of the fear’s power away. The Patient Perspective: What This Fear Feels Like From The Inside Research gives us numbers. Patients give us the meaning behind them. Across studies and cancer communities, a few themes come up again and again. “Everyone thinks I’m done. I don't feel done.” For many people diagnosed with early-stage breast cancer, the end of treatment is supposed to feel like a finish line. Instead, it can feel like losing the team that was watching over you. Friends and family celebrate, while the “survivor” quietly wonders whether every ache means something. “I can't plan too far ahead.” Fear can make it hard to book a trip, change jobs, or picture next year. Researchers note that fear of recurrence is linked to difficulty planning for the future, and to both avoiding checkups and over-checking. “My fear isn’t if. It's when and how fast.” People living with MBC often describe a different kind of fear. It may center on the next scan, on how many treatment options remain, or on what progression will mean for their family and daily life. In one study, people living with MBC said clearly that they wanted tools for living well with a cancer that will likely progress, not advice written for people hoping it never returns. “I feel that others want me to just stay positive.” Some people feel pressure to stay positive at all times or that their fear is not valid when they should be grateful. Fear isn’t a contest, and it isn’t a failure of hope. “It got easier when I talked about it.” Many people describe relief once they named their fear with a counselor, a support group, or their oncology team, and realized how common it is. If any of these sound familiar, please hear this: your feelings make sense, and support is available. When To Ask For More Support It may be time to reach out if fear: • Takes up a large part of most days • Keeps you from sleeping, working, or enjoying things you used to • Leads you to skip appointments, or to check your body constantly • Comes with ongoing sadness, hopelessness, or panic ASCO recommends that everyone with cancer be checked for anxiety and depression regularly throughout their care, and that psychological therapies like CBT be offered as a first step. You can ask for that support. You don’t need to wait for someone to offer it. If you ever have thoughts of harming yourself, call or text 988 (the Suicide and Crisis Lifeline in the U.S.) or seek emergency care right away. Questions To Bring To Your Care Team 1. Is what I’m feeling a common reaction at this stage of my care? 2. Which symptoms should I call you about, and which can I watch for a while? 3. How and when will I get my scan or test results? 4. Can you refer me to a counselor, psychologist, or social worker who works with people with cancer? 5. Are there programs, support groups, or online tools for fear of recurrence or fear of progression that you recommend? 6. For MBC: can we talk about what to expect, at the level of detail I’m comfortable with? Fear may always be part of the story. But it doesn’t have to write the whole story. With the right tools and support, many people find they can carry it more lightly and make room again for the life they want to live. This article is for educational purposes only and does not replace advice from your healthcare team. Research reviewed 2026. References 1. Luigjes-Huizer YL, Tauber NM, Humphris G, et al. What is the prevalence of fear of cancer recurrence in cancer survivors and patients? A systematic review and individual participant data meta-analysis. Psycho-Oncology. 2022;31(6):879-892. doi:10.1002/pon.5921. Link 2. Park SY, Lim JW. Cognitive behavioral therapy for reducing fear of cancer recurrence (FCR) among breast cancer survivors: a systematic review of the literature. BMC Cancer. 2022. doi:10.1186/s12885-021-08909-y. Link 3. Butow PN, Turner J, Gilchrist J, et al. Randomized trial of ConquerFear: a novel, theoretically based psychosocial intervention for fear of cancer recurrence. Journal of Clinical Oncology. 2017;35(36):4066-4077. doi:10.1200/JCO.2017.73.1257. Link 4. ConquerFear-Group: a randomized controlled trial of an online-delivered group-based psychological intervention for fear of cancer recurrence in breast cancer survivors. Psycho-Oncology. doi:10.1002/pon.6193. Link 5. Lengacher CA, Shelton MM, Reich RR, et al. Mindfulness based stress reduction (MBSR(BC)) in breast cancer: evaluating fear of recurrence (FOR) as a mediator of psychological and physical symptoms in a randomized control trial (RCT). Journal of Behavioral Medicine. 2014;37:185-195. doi:10.1007/s10865-012-9473-6. Link 6. Lengacher CA, Johnson-Mallard V, Post-White J, et al. Randomized controlled trial of mindfulness-based stress reduction (MBSR) for survivors of breast cancer. Psycho-Oncology. 2009;18:1261-1272. 7. Carlson LE, et al. Integrative oncology care of symptoms of anxiety and depression in adults with cancer: Society for Integrative Oncology–ASCO guideline. Journal of Clinical Oncology. 2023;41(28):4562-4591. doi:10.1200/JCO.23.00857. Link 8. Andersen BL, Lacchetti C, Ashing K, et al. Management of anxiety and depression in adult survivors of cancer: ASCO guideline update. Journal of Clinical Oncology. 2023. doi:10.1200/JCO.23.00293. Link 9. Rodin G, Lo C, Rydall A, et al. Managing Cancer and Living Meaningfully (CALM): a randomized controlled trial of a psychological intervention for patients with advanced cancer. Journal of Clinical Oncology. 2018;36(23):2422-2432. doi:10.1200/JCO.2017.77.1097. Link 10. Feasibility, acceptability, and preliminary efficacy of a self-directed online psychosocial intervention for women with metastatic breast cancer: Finding My Way-Advanced (pilot randomized controlled trial). Link 11. Finding My Way-Advanced: a pilot evaluation of a self-directed online psychosocial intervention in improving fear of cancer progression, distress and QOL in metastatic breast cancer. Oral presentation, Cancer Survivorship Conference 2023. Link 12. Tsai JJ, Wu CJ, Hu HF, Wang YJ. Symptom severity subgroups and individual symptom-associated risk for fear of progression in metastatic breast cancer. Oncology Nursing Forum. 2026;53(3). doi:10.1188/26.ONF.e26535304. Link 13. Psychological intervention reduces cancer survivors' fear of recurrence. Healio. June 2017 (news report of ConquerFear investigators' 2017 ASCO presentation; secondary source). Link Read More: When Waiting for Test Results Breaks Your Trust in Good News The Transformative Power of Art Therapy in Cancer Survivorship 20 Sleep Hacks For A Better Night's Rest Breast Cancer and Mental Health: Recognizing and Addressing Depression and Anxiety On the Podcast: Breast Cancer Conversations Episode 310. Surviving Cancer Is Only the Beginning: How to Process What Comes After Share your story, poetry, or art: https://www.survivingbreastcancer.org/submit-breast-cancer-story Connect with SurvivingBreastCancer.org Podcast Weekly Meetup Free Events
- GLP-1 Medications and Breast Cancer: What the Research Says So Far
A clear, balanced look at a fast-moving area of research, and what it means for people living with and beyond breast cancer. By Laura Carfang, Ed.D. EDUCATION | NUTRITION & DIET You’ve probably heard the names: Ozempic, Wegovy, Mounjaro, Zepbound. These medications are everywhere right now, in the news, on social media, and in conversations with friends. In our breast cancer community, the questions come up often. Is it safe for me be on a GLP-1? Could it help lower my risk of the cancer coming back? Can I take it while I’m on treatment? These are smart questions, and they deserve honest answers. The short version: the research is promising in places, early in others, and not yet settled. Here’s what we know so far. Key Takeaways GLP-1 medications such as semaglutide and tirzepatide were developed for diabetes and are now also used for weight management. A review of 52 randomized trials found no increase in breast cancer risk with GLP-1 medications. A large 2026 study linked GLP-1 use to lower recurrence and death in breast cancer patients with obesity or diabetes, but it was observational and can’t prove cause and effect. People with a history of breast cancer were excluded from the main GLP-1 trials, and breast cancer–specific trials are just beginning. GLP-1s can affect how oral medications are absorbed and can add to treatment side effects, so decisions should involve your oncology team. First, what are GLP-1 medications? GLP-1 stands for glucagon-like peptide-1, a hormone your body naturally makes after you eat. It tells your body to release insulin, slows how quickly your stomach empties, and helps you feel full. GLP-1 medications copy or boost this hormone, and their effects last much longer. They were first developed for type 2 diabetes. Some are now also approved for weight management and for lowering heart risk in certain people. Common examples include semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound). Tirzepatide acts on GLP-1 and a second hormone, GIP. We’re naming them here only to help you recognize them, not to recommend any brand. Why metabolic health matters in breast cancer “Metabolic health” describes how well your body manages energy: blood sugar, insulin, body fat, cholesterol, and blood pressure. Researchers have long studied how it connects to breast cancer. Here’s what the evidence shows: • Weight and outcomes are linked. Studies have associated obesity with a higher risk of breast cancer recurrence and death. The link appears strongest in postmenopausal women and in hormone receptor-positive breast cancer. • Fat tissue makes estrogen. After menopause, body fat becomes a main source of estrogen, which can fuel hormone receptor-positive breast cancer. • Insulin may play a role. Higher insulin levels have been tied to higher breast cancer risk and to worse outcomes in some studies, even in women without diabetes. • Inflammation adds to the picture. Excess body fat is associated with ongoing, low-level inflammation that researchers believe may affect cancer growth. Treatment itself can make this harder. Many people gain weight during chemotherapy, steroid use, or years of endocrine (hormone) therapy, and lose muscle along the way. That’s exactly why GLP-1 medications have caught researchers’ attention. The question is whether they help people with breast cancer beyond managing weight and blood sugar. One important note: weight is never a measure of your worth, and no one causes their own cancer. This is about understanding biology, not assigning blame. What the research says right now Do GLP-1 medications raise breast cancer risk? Current evidence says no. A review of 52 randomized trials, covering more than 48,000 people on GLP-1 medications and nearly 41,000 who weren’t, found no increase in breast cancer or in benign breast lumps. These trials were in people with diabetes or excess weight, not in breast cancer survivors specifically. Could they lower the risk of recurrence? This is where the headlines come from, and where it’s important to slow down. In May 2026, a large study in JAMA Network Open looked at health records from more than 841,000 patients with breast cancer. Among patients with obesity or type 2 diabetes, those who used GLP-1 medications had lower rates of death and recurrence over 10 years than similar patients who didn’t. That sounds dramatic, and it may turn out to be meaningful. But there are real limits: • It’s an observational study. It looked back at records. It didn’t randomly assign people to a medication, so it can show a link but can’t prove cause and effect. • Other differences may explain it. People who get these medications may have better access to care, or other health differences that affect outcomes. • Experts raised concerns. Some independent researchers questioned the study’s methods and urged caution in drawing conclusions about breast cancer specifically. • Heart health may be part of the story. Many women treated for breast cancer ultimately face heart disease, and GLP-1s are known to lower heart risk. That may explain some of the survival difference, but not necessarily the recurrence finding. The study’s own authors said clinical trials are needed before these medications can guide cancer treatment decisions. What studies are underway? Randomized trials designed specifically for breast cancer are just getting started. Examples include: • A trial testing tirzepatide alongside standard hormone therapy in people with overweight or obesity and high-risk, hormone receptor-positive early breast cancer. • A study of tirzepatide in women who are postmenopausal and have been diagnosed with HR+ breast cancer of hormone receptor-positive breast cancer with obesity, looking at weight, body composition, and overall health. • A Mayo Clinic trial testing whether semaglutide plus lifestyle support improves heart and blood vessel health in survivors taking aromatase inhibitors. These trials will take years. Until then, GLP-1 medications are not a breast cancer treatment, and they’re not a substitute for proven therapies. Risks and considerations A history of breast cancer doesn’t automatically rule out a GLP-1 medication. But it does mean the decision should be made together with your oncology team, not just the prescriber of the GLP-1. Here’s what to weigh. People with breast cancer weren’t in the main trials. The large studies that led to FDA approval of semaglutide and tirzepatide for weight loss excluded people with a history of breast cancer. Early studies in survivors have found weight loss and side effects similar to people without cancer, but the data are still limited. Effects on oral cancer medications. GLP-1s slow how quickly the stomach empties. That can change the timing of when pills are absorbed. Experts say this deserves a conversation if you take oral cancer drugs, such as anti-estrogen pills or capecitabine (Xeloda). Severe vomiting can also mean losing a dose entirely. Overlapping side effects during treatment. Nausea, vomiting, constipation, and reduced appetite are common with GLP-1s, and with chemotherapy. Taking both can make it hard to tell what’s causing what, and harder to eat enough. Many teams pause GLP-1s during intense treatment, but this is decided case by case. Muscle and bone. A meaningful share of the weight lost on GLP-1s can come from muscle, not just fat. Cancer treatment can already reduce muscle and bone strength. Adequate protein, strength training, and nutrition support matter. Thyroid history. People with a personal or family history of certain thyroid cancers (medullary thyroid cancer) or a related genetic syndrome are advised not to use these medications. Cost and access. Coverage varies widely, and supply and pricing have shifted. Compounded or online versions aren’t held to the same standards as FDA-approved products, so talk with your team before going that route. Questions to bring to your care team 1. Given my diagnosis and treatment, is a GLP-1 medication something to consider for me? 2. Could it interact with any of my cancer medications, especially pills I take by mouth? 3. Should I pause it during chemotherapy, surgery, or other treatment? 4. How will we protect my muscle and bone health if I lose weight? 5. Who should manage this medication, and how will they coordinate with my oncologist? 6. Are there clinical trials studying GLP-1 medications in people like me? 7. What other ways can we support my metabolic health, like nutrition, physical activity, or sleep? The bottom line GLP-1 medications are one of the most talked-about developments in medicine, and their connection to breast cancer is worth watching closely. Early data are encouraging, and safety data so far are reassuring. But we don’t yet have the randomized trials needed to know whether these medications change breast cancer outcomes. For now, the best approach is an informed, individual conversation with your care team, one that weighs your health goals, your treatment, and the full picture of benefits and risks. Note: This article offers general information and does not replace professional medical advice. Make sure to discuss your options with your healthcare provider. Read More: The Role of Nutrition in Breast Cancer Recovery: Optimizing Your Diet for Healing Understanding and Managing GI Issues Caused by Breast Cancer Treatment GLP-1 Medications and Breast Cancer: What the Latest Research Really Means On the Podcast: Breast Cancer Conversations Episode 291. Breast Cancer Survivorship: Exercise, Nutrition, Sleep, and Support Share your story, poetry, or art: https://www.survivingbreastcancer.org/submit-breast-cancer-story Connect with SurvivingBreastCancer.org Podcast Weekly Meetup Free Events
- When Your Symptoms Don’t Show Up on a Test
There is a stretch in which you feel unwell and every test says you are fine. It has a name, and knowing it changes the conversation you can have with your care team. By Laura Carfang, Ed.D. EDUCATION | SURGERY When Your Symptoms Don’t Show Up on a Test You know something has changed. The fatigue is not the ordinary kind. There is a heaviness, or a tightness, or a headache that keeps returning. You bring it up, and the workup comes back clean. So you are sent to someone else. Then someone else. Each visit begins again from the top, and each one ends with a version of the same sentence: your labs look good. At SurvivingBreastCancer.org we hear this constantly, and the detail that comes up again and again is not pain. It is the feeling of not being believed — or, more precisely, of not being measurable. Nobody has told you that you are imagining it. They have simply run out of tests to run. That stretch has a name. It is not a diagnosis, and naming it does not explain what is happening in any particular body. But it does something useful: it gives you language for a real clinical situation, instead of leaving you to wonder whether the problem is you. Listen Now The prodromal phase On a recent episode of Breast Cancer Conversations, Dr. Robert Whitfield, a plastic and reconstructive surgeon in Austin who spent fifteen years in cancer reconstruction, described it in a way that landed. He was talking about how obvious a problem is once it declares itself. If someone arrives with a red, swollen, painful chest and a fever, nobody is confused. Everyone knows what that is and what to do about it. But before that, he said, there is a prodromal phase. You are getting sick, but you are not sick yet. The word comes from medicine’s oldest vocabulary. A prodrome is the early stage of an illness, the part that precedes the signs anyone can point to. The body has begun responding to something. The response has not yet crossed the threshold where our instruments can see it. Medicine is built around thresholds. A fever is a number. An elevated marker is a number. Redness and swelling are visible. These are good tools, and they work well for the problems they were designed to catch. What they are not built for is the interval before the number moves. Why the standard workup comes back clean When you describe vague, systemic symptoms, a clinician usually reaches for the same handful of tests. Dr. Whitfield named them directly, and was blunt about their limits. C-reactive protein (CRP) rises with significant inflammation. Sed rate (erythrocyte sedimentation rate) is an older, broader inflammation marker. IL-6 is a signaling molecule involved in inflammatory response. All three are useful. All three are also blunt instruments, and in his experience they typically read normal in exactly the situation being described. His phrasing was that these tests are antiquated, not useless, but not designed for this question. There is no single blood panel you can order that settles it. A normal result means the test did not detect the thing it measures. It does not mean nothing is happening. Those are different statements, and in a fifteen-minute appointment they collapse into one. One place this shows up: implants Before going further, I want to if you have implants and you feel well, this is not a warning about your body. Most people with implant reconstruction respond incredible well fine. This section is here because implants are a clear, well-studied example of the gap described above and not because having them means something is wrong. What is firmly established is capsular contracture. Your body forms a capsule of scar tissue around any implant; that is normal and expected. In some people that capsule thickens and tightens, and the breast becomes firm, higher-riding, misshapen or painful. It is graded on a four-point scale, it is recognized by every plastic surgeon, and there are established ways to manage it. If this is what you have, you are on well-mapped ground. There is also BIA-ALCL — breast implant-associated anaplastic large cell lymphoma. It is rare, it is recognized by the FDA, and it has been linked primarily to textured implants. The usual presenting sign is late swelling or fluid collection around the implant, often years after surgery. It is worth knowing the name so you can ask about it directly. And then there is the territory that is still being worked out. Dr. Whitfield’s practice began sending capsule tissue for PCR analysis rather than relying only on traditional culture, on the reasoning that conventional culture requires bacteria to be alive and present in enough quantity to grow, while PCR detects genetic material either way. His published series found bacterial contamination in 29% of samples. That figure needs its denominator, and he supplied it himself in the interview. It is 29% of the tissue samples from his own patients — people who had already sought him out with problems and had elected to have implants removed. It is not 29% of women with implants. Asked directly whether it could be generalized, he said no, and added that nobody has the population number. He was equally plain that a positive finding does not establish cause. His words were that we do not know how much it contributes in any individual person. The honest summary is that this is an area where the science is still catching up with what patients report. Dr. Whitfield said as much, and pointed to a 2025 study from Denmark examining immune cell activity in capsule tissue as the kind of work that will eventually produce better answers. What you can actually do Write it down as it happens. Date, symptom, how long, what you were doing, how bad out of ten. A pattern across six weeks is evidence. Give it a shape before you walk in. One sentence: what changed, when it started, and what you want from this visit. Clinicians are working inside short appointments. A clear opening sentence is not pushiness; it is the most useful gift you can hand them. Ask the question underneath the answer. When a test comes back normal, a fair follow-up is: what would this test have caught, and what would it miss? It is a real question with a real answer, and it moves the conversation forward instead of ending it. Keep the whole team informed. If you have implants, make sure your oncologist, your primary care physician and your plastic surgeon are all aware of what you are experiencing. A symptom that looks unremarkable to one of them may matter to another. A second opinion is a normal thing to seek. If your workup is complete, your symptoms persist, and the conversation has stalled, asking someone else to look is reasonable medical practice. It is not disloyalty to your team. And if you are weighing removal: that is a surgical decision, with its own risks and its own recovery, to be made with your own team. There is no single correct answer, and anyone who tells you otherwise — in either direction — is overstating what is known. Note: This article offers general information and does not replace professional medical advice. Make sure to discuss your options with your healthcare provider. Read More: Exploring Breast Reconstruction Surgery: Pros and Cons Breast Reconstruction Surgery: Options, Considerations, and Recovery Going Flat and Explant Surgery On the Podcast: Breast Cancer Conversations Episode 318. When Breast Reconstruction Causes Problems with Dr. Whitfield Share your story, poetry, or art: https://www.survivingbreastcancer.org/submit-breast-cancer-story Connect with SurvivingBreastCancer.org Podcast Weekly Meetup Free Events
Podcasts (85)
- Subscribe to our Newsletter | Surviving Breast Cancer
Subscribe to the Surviving Breast Cancer newsletter for updates on community support, programs, content, and medical breakthroughs for breast cancer patients. Subscribe To Our Weekly Monday Mailing List! First name Last name Email Yes, subscribe me to your newsletter. Occasionally we host in-person events. If you let us know where you are from we'll keep you posted when we are in your area! Multi-line address Country/Region Address City Zip / Postal code Submit
- Breast Cancer Support for Patients & Survivors | SBC
SurvivingBreastCancer.org offers breast cancer support through online programs, resources, and a caring community for patients, survivors, and their families. When breast cancer becomes part of your life, SBC becomes part of your support. Subscribe to the Newsletter Donate BREAST CANCER AWARENESS MONTH. TELL CANCER TO TAKE A HIKE Climb a mountain trail or walk around your block, every step you take this October funds free support groups, education, navigation, and financial help for people diagnosed with breast cancer. Start Your Hike/Walk Donate SurvivingBreastCancer.org (SBC) transforms how people experience breast cancer by bridging clinical care and everyday life. Find Support JOIN THE COMMUNITY Download the SurvivingBreastCancer.org App Your on-the-go companion for trusted education, meaningful community, and programs designed to support you through every stage of the breast cancer experience. Download from the App Store Download from Google Play Discover Progams Explore over 300 programs Whole-person support including support groups, mind-body wellness classes, expert-led webinars Move & Restore Meditation Movement Classes Pilates & Yoga Guided Hypnosis & Forest Bathing Movement Classes Pilates & Yoga Guided Hypnosis & Forest Bathing Menu Close Create & Express Art Expression Book Club Expressive Writing Crochet & Fiber Arts Menu Close Connect & Support Early Stage (0-III) Metastatic (IV) Inflammatory (IBC) Lymphedema Support Caregivers All Stages En Espanol Menu Close Explore All Programs YOUR AI-POWERED CARE NAVIGATOR Ask Emma Ask Emma, SBC’s virtual support guide, designed to help you quickly navigate programs, resources, and answers tailored to your needs. Whether you’re looking for support, education, or where to start, Emma is here 24/7 to point you in the right direction. One Community One Rocket One Massive Impact Join 30,000+ readers who receive our weekly Monday newsletter Recibe nuestro boletín en Español First name* Last name Email* Yes, subscribe me to the SBC Monday newsletter. * Submit Registrate aquí Shop Now This October, SurvivingBreastCancer.Org is honored to partner with Madam Glam in our shared mission to support breast cancer awareness and action. For every pink gel sold from Madam Glam’s exclusive "Think Pink" Collection, $1 will be donated directly to SurvivingBreastCancer.Org.
- Our Team | Surviving Breast Cancer
Meet the Team Laura Carfang, M.A., Ed.D. William Laferriere, MBA Meghann Sweeney, J.D. Tony Carfang, MBA Board of Directors Laura Carfang, M.A., Ed.D. Chief Executive Officer, Founder, Board Member Laura@survivingbreastcancer.org William Laferriere, MBA Chief Visionary Officer & VP Business Development Founder, Board Member William@survivingbreastcancer.org Nancy Gaulin Psy.D. Board Member Tony Carfang, MBA Board Member Brad Carver Board Member SurvivingBreastCancer.org . Medical Advisory Board Dr. Amy Commander, MD Medical Director, Mass General Cancer Center-Waltham Director, Breast Oncology Program at Newton-Wellesley Hospital Director, Lifestyle Medicine Dr. Rachel Jimenez, MD Dr. Rachel Jimenz,, MD Associate Program Director, Harvard Radiation Oncology Residency Program Dr. Jandie Posner Jandie Posner, DO FACS. board-certified surgeon Jefferson Health Our Incredible Administration The hands on the ground making the dream work! Laura Carfang Chief Executive Officer, Founder, Board Member Laura@survivingbreastcancer.org Meghan McCallum Excecutive Assistant meghan@survivingbreastcancer.org Elisa Herrera Director of Programs and Events & Hispanic Outreach elisa@survivingbreastcancer.org Itzel Herrera Social Media Coordinator @survivingbreastcancer.org Spanish Leadership Team Brenda Coronado Despues de un Diagnóstico brenda@survivingbreastcancer.org Lourdes Heras Despues de un Diagnóstico lourdes@survivingbreastcancer.org Our Instructors The hands and hearts creating space for healing. Our Early Stage volunteer Leadership Team Pooja Jain Julie Cottril l Meghan Staskal-Bradt Carol Collins Denise Whittaker Our MBC Volunteer Leadership Team Amy Russell-Parliman Kathleen Friel Hillary Stackpole Jo Lynn Collins Kacie Flaherty Elena Hatzakos Donna Charlevoix Kadesha Ferguson






